 Ryan Lanning
Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 4 | 2024 | 760 | 0.850 |
Why?
| | Skin Neoplasms | 4 | 2024 | 855 | 0.770 |
Why?
| | Sarcoma | 1 | 2024 | 188 | 0.740 |
Why?
| | Immunotherapy | 1 | 2024 | 641 | 0.620 |
Why?
| | Trastuzumab | 1 | 2015 | 96 | 0.450 |
Why?
| | Receptor, ErbB-2 | 1 | 2015 | 341 | 0.380 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 1079 | 0.380 |
Why?
| | Radiotherapy, Adjuvant | 3 | 2024 | 220 | 0.350 |
Why?
| | Antineoplastic Agents | 3 | 2019 | 2129 | 0.310 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2017 | 683 | 0.270 |
Why?
| | Laryngeal Neoplasms | 2 | 2017 | 39 | 0.270 |
Why?
| | Microscopy | 2 | 2022 | 152 | 0.240 |
Why?
| | Acoustics | 1 | 2025 | 42 | 0.240 |
Why?
| | Breast Neoplasms | 3 | 2015 | 2253 | 0.230 |
Why?
| | Hutchinson's Melanotic Freckle | 1 | 2024 | 3 | 0.220 |
Why?
| | Carcinoma | 2 | 2017 | 240 | 0.220 |
Why?
| | Combined Modality Therapy | 2 | 2024 | 1236 | 0.200 |
Why?
| | Contrast Media | 2 | 2025 | 467 | 0.200 |
Why?
| | Neoplasms | 6 | 2022 | 2671 | 0.190 |
Why?
| | Mammary Neoplasms, Experimental | 2 | 2019 | 68 | 0.170 |
Why?
| | Glottis | 2 | 2017 | 20 | 0.170 |
Why?
| | Head and Neck Neoplasms | 2 | 2017 | 606 | 0.170 |
Why?
| | Drug Carriers | 1 | 2019 | 128 | 0.140 |
Why?
| | Chemoradiotherapy | 2 | 2017 | 225 | 0.140 |
Why?
| | Oxygen | 4 | 2022 | 931 | 0.140 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2017 | 21 | 0.140 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2017 | 10 | 0.130 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2017 | 389 | 0.130 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2017 | 16 | 0.130 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2017 | 17 | 0.130 |
Why?
| | Cisplatin | 1 | 2019 | 320 | 0.130 |
Why?
| | Nose Neoplasms | 1 | 2017 | 25 | 0.130 |
Why?
| | Meningioma | 1 | 2018 | 91 | 0.130 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2017 | 28 | 0.130 |
Why?
| | Meningeal Neoplasms | 1 | 2018 | 100 | 0.130 |
Why?
| | Dexamethasone | 1 | 2019 | 368 | 0.130 |
Why?
| | Ear Neoplasms | 1 | 2016 | 9 | 0.130 |
Why?
| | Ear Canal | 1 | 2016 | 15 | 0.130 |
Why?
| | Misonidazole | 1 | 2016 | 1 | 0.130 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2016 | 22 | 0.130 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2016 | 35 | 0.130 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 130 | 0.120 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2016 | 63 | 0.120 |
Why?
| | Brachytherapy | 1 | 2016 | 121 | 0.120 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2016 | 142 | 0.120 |
Why?
| | Mastectomy | 1 | 2015 | 137 | 0.110 |
Why?
| | Humans | 20 | 2024 | 137585 | 0.110 |
Why?
| | Quantum Dots | 1 | 2013 | 37 | 0.100 |
Why?
| | Protein Array Analysis | 1 | 2013 | 57 | 0.100 |
Why?
| | Lymphatic Metastasis | 1 | 2015 | 352 | 0.100 |
Why?
| | Nanoparticles | 1 | 2019 | 481 | 0.100 |
Why?
| | Disease-Free Survival | 1 | 2015 | 686 | 0.100 |
Why?
| | Optics and Photonics | 2 | 2003 | 43 | 0.100 |
Why?
| | Propensity Score | 3 | 2017 | 294 | 0.090 |
Why?
| | Aged | 8 | 2018 | 23961 | 0.090 |
Why?
| | Spectroscopy, Near-Infrared | 2 | 2002 | 59 | 0.090 |
Why?
| | Neoplasm Metastasis | 3 | 2019 | 658 | 0.080 |
Why?
| | Fluorescence Recovery After Photobleaching | 1 | 2009 | 20 | 0.080 |
Why?
| | Cell Physiological Phenomena | 1 | 2009 | 19 | 0.080 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1266 | 0.080 |
Why?
| | Middle Aged | 9 | 2018 | 33479 | 0.080 |
Why?
| | Extracellular Fluid | 1 | 2009 | 31 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2017 | 7635 | 0.080 |
Why?
| | Palliative Care | 1 | 2015 | 758 | 0.070 |
Why?
| | Glucose | 1 | 2013 | 1020 | 0.070 |
Why?
| | Male | 9 | 2024 | 67762 | 0.070 |
Why?
| | Female | 15 | 2019 | 73304 | 0.070 |
Why?
| | Neoplasm Staging | 2 | 2024 | 1389 | 0.070 |
Why?
| | Young Adult | 4 | 2017 | 13209 | 0.070 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 332 | 0.060 |
Why?
| | Tumor Microenvironment | 2 | 2022 | 674 | 0.060 |
Why?
| | Blood Vessels | 1 | 2007 | 187 | 0.060 |
Why?
| | Radiotherapy Dosage | 2 | 2016 | 268 | 0.060 |
Why?
| | X-Rays | 1 | 2025 | 28 | 0.060 |
Why?
| | Volatilization | 1 | 2025 | 56 | 0.060 |
Why?
| | Adult | 7 | 2018 | 37929 | 0.060 |
Why?
| | Imaging, Three-Dimensional | 1 | 2009 | 580 | 0.060 |
Why?
| | Fetal Blood | 1 | 2007 | 327 | 0.060 |
Why?
| | Microbubbles | 1 | 2025 | 49 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 889 | 0.060 |
Why?
| | Metal Nanoparticles | 1 | 2025 | 83 | 0.060 |
Why?
| | Gold | 1 | 2025 | 118 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 1 | 2007 | 406 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1509 | 0.050 |
Why?
| | Spectrophotometry | 1 | 2002 | 61 | 0.050 |
Why?
| | Angiotensins | 1 | 2022 | 9 | 0.050 |
Why?
| | Receptors, Angiotensin | 1 | 2022 | 12 | 0.050 |
Why?
| | Losartan | 1 | 2022 | 14 | 0.050 |
Why?
| | Survival Rate | 2 | 2017 | 1972 | 0.050 |
Why?
| | Temperature | 1 | 2025 | 679 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2007 | 785 | 0.050 |
Why?
| | Medical Oncology | 1 | 2024 | 289 | 0.050 |
Why?
| | Databases, Factual | 2 | 2017 | 1357 | 0.040 |
Why?
| | Mice | 5 | 2022 | 17787 | 0.040 |
Why?
| | Time Factors | 5 | 2017 | 6828 | 0.040 |
Why?
| | Neoplasm Transplantation | 3 | 2009 | 257 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2003 | 3566 | 0.040 |
Why?
| | Mammography | 1 | 2002 | 154 | 0.040 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2021 | 115 | 0.040 |
Why?
| | Animals | 8 | 2022 | 36940 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 2021 | 171 | 0.040 |
Why?
| | Diffusion | 2 | 2011 | 116 | 0.040 |
Why?
| | Photons | 1 | 2000 | 70 | 0.040 |
Why?
| | Micelles | 1 | 2019 | 39 | 0.040 |
Why?
| | Mice, Nude | 1 | 2019 | 698 | 0.030 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2017 | 43 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 5742 | 0.030 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2017 | 40 | 0.030 |
Why?
| | Margins of Excision | 1 | 2017 | 50 | 0.030 |
Why?
| | Organs at Risk | 1 | 2016 | 32 | 0.030 |
Why?
| | Tumor Hypoxia | 1 | 2016 | 7 | 0.030 |
Why?
| | Radiometry | 1 | 2016 | 50 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1272 | 0.030 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 70 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 2003 | 940 | 0.030 |
Why?
| | Radiation Protection | 1 | 2016 | 38 | 0.030 |
Why?
| | Cochlea | 1 | 2016 | 72 | 0.030 |
Why?
| | United States | 3 | 2017 | 14841 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2016 | 178 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2017 | 230 | 0.030 |
Why?
| | Hypoxia | 1 | 2022 | 1112 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2016 | 294 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2017 | 404 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2017 | 491 | 0.030 |
Why?
| | Boronic Acids | 1 | 2013 | 37 | 0.030 |
Why?
| | Infant | 2 | 2017 | 9465 | 0.020 |
Why?
| | Rats, Inbred F344 | 2 | 2003 | 265 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2018 | 10811 | 0.020 |
Why?
| | Rats | 3 | 2009 | 5647 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1289 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2013 | 560 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2013 | 321 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2074 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 2021 | 1238 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3412 | 0.020 |
Why?
| | Scattering, Radiation | 2 | 2002 | 101 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2757 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2013 | 365 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1692 | 0.020 |
Why?
| | Lymphography | 1 | 2009 | 10 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2018 | 15657 | 0.020 |
Why?
| | Subcutaneous Tissue | 1 | 2009 | 24 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2017 | 986 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 194 | 0.020 |
Why?
| | Chickens | 1 | 2009 | 191 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 298 | 0.020 |
Why?
| | Fluorescein Angiography | 1 | 2009 | 151 | 0.020 |
Why?
| | Collagen Type I | 1 | 2009 | 136 | 0.020 |
Why?
| | Microvessels | 1 | 2009 | 88 | 0.020 |
Why?
| | Prognosis | 1 | 2017 | 4030 | 0.020 |
Why?
| | Image Enhancement | 1 | 2009 | 190 | 0.020 |
Why?
| | Equipment Design | 1 | 2009 | 522 | 0.020 |
Why?
| | Adolescent | 2 | 2017 | 21513 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 2007 | 78 | 0.020 |
Why?
| | Hyaluronic Acid | 1 | 2009 | 225 | 0.020 |
Why?
| | Cell Separation | 1 | 2007 | 318 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2691 | 0.020 |
Why?
| | Glioblastoma | 1 | 2009 | 345 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2017 | 6079 | 0.010 |
Why?
| | Prospective Studies | 1 | 2017 | 7604 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4295 | 0.010 |
Why?
| | Methylene Blue | 1 | 2002 | 24 | 0.010 |
Why?
| | Indocyanine Green | 1 | 2002 | 24 | 0.010 |
Why?
| | Coloring Agents | 1 | 2002 | 87 | 0.010 |
Why?
| | Fibroadenoma | 1 | 2002 | 2 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11074 | 0.010 |
Why?
| | Cell Line | 1 | 2007 | 2847 | 0.010 |
Why?
| | Algorithms | 1 | 2009 | 1704 | 0.010 |
Why?
| | Premenopause | 1 | 2002 | 131 | 0.010 |
Why?
| | Breast | 1 | 2002 | 151 | 0.010 |
Why?
| | Radiography | 1 | 2002 | 822 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2007 | 2475 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2002 | 840 | 0.010 |
Why?
| | Kinetics | 1 | 2002 | 1670 | 0.010 |
Why?
| | Water | 1 | 2002 | 460 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2002 | 518 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2002 | 578 | 0.010 |
Why?
| | Hemoglobins | 1 | 2000 | 353 | 0.010 |
Why?
| | Child | 1 | 2017 | 21935 | 0.010 |
Why?
|
|
Lanning's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|